OWL 4130
Alternative Names: OWL-4130Latest Information Update: 02 Feb 2024
At a glance
- Originator Owl Therapeutics
- Class Recombinant fusion proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Encephalitis
Most Recent Events
- 21 Dec 2023 Preclinical trials in Inflammation in USA (Parenteral) (Owl Therapeutics pipeline, December 2023)